Bohai Pharmaceuticals Group Inc. is a producer, manufacturer and distributor of herbal medicines based on traditional Chinese medicines in China. The company’s products are sold over-the-counter through local pharmacies and retail drug store chains as well as by prescription through hospitals.

The company today announced the appointment of a new independent director, Anthony Chan, to its board of directors. Bohai also appointed its chief financial officer, Gene Hsiao, to the board of directors. As a result of these two additions, Bohai’s board now has six members, four of whom are independent as defined by SEC and NASDAQ rules.

Mr. Chan brings nearly 30 years of experience in finance and management to Bohai. He currently serves as chief financial officer at a leading Chinese mobile phone manufacturer, Zoom Technologies. Previously, Mr. Chan served as an Asian investment bank consultant to GunnAllen Financial. He also was CFO and director of the board at US internet company hereUare Inc. In addition, he served as a financial advisor and CEO at two other NASDAQ-listed companies.

Mr. Hsiao joined Bohai Pharmaceuticals as CFO in June 2010. He has over 15 years of SEC accounting, corporate finance and public company management experience. Since joining the company, he has overseen all of Bohai’s financial reporting and related company procedures.

In addition, Bohai has formally established three independent board committees – an audit committee, nominating and corporate governance committee and compensation committee. The formation of these committees is a requirement for uplisting to the NASDAQ.

For more information on Bohai Pharmaceuticals, please visit its website at